Orserdu combinations show favorable safety profiles for ER+, HER2- metastatic breast cancer in phase Ib/II trials

NCI’s Virtual Clinical Trials Office fills the staffing shortages at cancer centers

Cancer centers that continue to experience pandemic-induced shortages in staffing their clinical research enterprise may soon be able to rely on support from NCI’s Virtual Clinical Trials Office to open studies and accrue patients.

June 28, 2024

Vol.50 No.26

By Matthew Bin Han Ong

White House

At White House forum, Bertagnolli, Califf, Wegrzyn call for greater innovation in clinical trials

Leaders of three health agencies presented new initiatives focused on patient-centered research, diversity in clinical trial enrollment, and innovation in clinical research.

June 28, 2024

Vol.50 No.26

By McKenzie Prillaman

In Brief

UAMS Winthrop P. Rockefeller Cancer Institute receives five NCI grants

Researchers at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences have been awarded five grants from NCI in 2024, totaling $4.6 million.

June 28, 2024

Vol.50 No.26

Clinical Roundup

Tai Chi reduces risk of inflammatory disease, treats insomnia among breast cancer survivors

Both Tai Chi and cognitive behavioral therapy can reduce insomnia in breast cancer survivors but also may provide additional health benefits by reducing inflammation and bolstering anti-viral defenses, according to a study led by UCLA Health researchers. The work was published in Brain, Behavior, and Immunity.

June 28, 2024

Vol.50 No.26

Obituary

“Father of tamoxifen” V. Craig Jordan dies at 76

Pharmacologist V. Craig Jordan, a professor of Breast and Medical Oncology and Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer Center who discovered selective estrogen receptor modulators and developed breakthrough breast cancer treatments, died June 9 at his home in Houston.

June 14, 2024

Vol.50 No.24

By MD Anderson Cancer Center staff

In the Archives

In an interview and a memoir, V. Craig Jordan spoke about his life and SERMs

V. Craig Jordan, a pharmacologist who discovered selective estrogen receptor modulators, died on June 9. Jordan, a professor at The University of Texas MD Anderson Cancer Center who was credited with discovery of tamoxifen, was 76. An obituary appears in this issue. Jordan appeared on the Cancer History Project podcast in 2022 to discuss...

June 14, 2024

Vol.50 No.24

Orserdu combinations show favorable safety profiles for ER+, HER2- metastatic breast cancer in phase Ib/II trials

YOU MAY BE INTERESTED IN

NCI’s Virtual Clinical Trials Office fills the staffing shortages at cancer centers

At White House forum, Bertagnolli, Califf, Wegrzyn call for greater innovation in clinical trials

UAMS Winthrop P. Rockefeller Cancer Institute receives five NCI grants

Tai Chi reduces risk of inflammatory disease, treats insomnia among breast cancer survivors

“Father of tamoxifen” V. Craig Jordan dies at 76

In an interview and a memoir, V. Craig Jordan spoke about his life and SERMs

Renew today!

Subscriber content

Login